Zobrazeno 1 - 10
of 76
pro vyhledávání: '"Mikhail V, Ovanesov"'
Autor:
Wojciech Jankowski, Stepan S. Surov, Nancy E. Hernandez, Atul Rawal, Marcos Battistel, Daron Freedberg, Mikhail V. Ovanesov, Zuben E. Sauna
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-9 (2024)
Abstract Direct oral anticoagulants (DOACs) targeting activated factor Xa (FXa) are used to prevent or treat thromboembolic disorders. DOACs reversibly bind to FXa and inhibit its enzymatic activity. However, DOAC treatment carries the risk of antico
Externí odkaz:
https://doaj.org/article/61c278e166c64672affea2a9f7d21b28
Autor:
Ivan D. Tarandovskiy, Stepan S. Surov, Leonid A. Parunov, Yideng Liang, Wojciech Jankowski, Zuben E. Sauna, Mikhail V. Ovanesov
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Thrombin generation (TG) and fibrin clot formation represent the central process of blood coagulation. Up to 95% of thrombin is considered to be generated after the clot is formed. However, this was not investigated in depth. In this study,
Externí odkaz:
https://doaj.org/article/dca2acebe37f4b8dbe886c06c41fd9bf
Publikováno v:
Thrombosis Journal, Vol 21, Iss 1, Pp 1-15 (2023)
Abstract Background Fluorogenic thrombin generation (TG) is a global hemostasis assay that provides an overall representation of hemostasis potential. However, the accurate detection of thrombin activity in plasma may be affected by artifacts inheren
Externí odkaz:
https://doaj.org/article/a8aca791941b4f26874d39baf9ca8f78
Autor:
William C. Chang, Joseph W. Jackson, Kellie R. Machlus, Alisa S. Wolberg, Mikhail V. Ovanesov
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 3, Pp 447-455 (2021)
Abstract Introduction The thrombin generation (TG) test is a global hemostasis assay sensitive to procoagulant conditions. However, some TG assays may underestimate elevated TG when the thrombin fluorogenic substrate is depleted or fluorescence is at
Externí odkaz:
https://doaj.org/article/935b161d5fba47678421fa79e99f597d
Autor:
Yideng Liang, Joseph W. Jackson, Samuel A. Woodle, Stepan S. Surov, Leonid A. Parunov, Dorothy E. Scott, Mark Weinstein, Timothy K. Lee, Mikhail V. Ovanesov
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 5, Iss 1, Pp 211-222 (2021)
Abstract Background Activated coagulation factor XIa (FXIa) is an impurity and primary source of procoagulant activity in thrombosis‐implicated immune globulin (IG) products. Several assays, of varying quality and precision are used to assess FXIa
Externí odkaz:
https://doaj.org/article/ab2eec995bec476b91c3b022656c3222
Autor:
Wojciech Jankowski, Joseph McGill, H.A.Daniel Lagassé, Stepan Surov, Gary Bembridge, Campbell Bunce, Edward Cloake, Mark H. Fogg, Katarzyna I. Jankowska, Abdul Khan, Joseph Marcotrigiano, Mikhail V. Ovanesov, Zuben E. Sauna
Publikováno v:
Blood Advances, Vol 3, Iss 17, Pp 2668-2678 (2019)
Abstract: Vatreptacog alfa (VA), a recombinant activated human factor VII (rFVIIa) variant with 3 amino acid substitutions, was developed to provide increased procoagulant activity in hemophilia patients with inhibitors to factor VIII or factor IX. I
Externí odkaz:
https://doaj.org/article/ef7a790689d44f5b9a7802adb877facf
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 4, Iss 5, Pp 944-945 (2020)
Externí odkaz:
https://doaj.org/article/b2f169bd185d433e85f9d7ad0aaab62e
Autor:
Tseday Z. Tegegn, Silvia H. De Paoli, Martina Orecna, Oumsalama K. Elhelu, Samuel A. Woodle, Ivan D. Tarandovskiy, Mikhail V. Ovanesov, Jan Simak
Publikováno v:
Journal of Extracellular Vesicles, Vol 5, Iss 0, Pp 1-13 (2016)
Background: Freezing is promising for extended platelet (PLT) storage for transfusion. 6% DMSO cryopreserved PLTs (CPPs) are currently in clinical development. CPPs contain significant amount of platelet membrane vesicles (PMVs). PLT-membrane changes
Externí odkaz:
https://doaj.org/article/d89077311f6b44bbbc16ca10675930b4
Autor:
Leonid A Parunov, Yideng Liang, Qijin Lu, Alexey M Shibeko, Erik I. Tucker, Timothy K. Lee, Fazoil I Ataullakhanov, Dorothy Scott, Mikhail V Ovanesov
Publikováno v:
Blood Advances.
Inhibitors of coagulation factor (F) XIa are currently investigated as potential anticoagulant therapies. We hypothesized that circulating FXIa may be a potential target for these therapies. Using previous analyses of FXIa impurity in immune globulin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25761cdb087100a2c10a3455f6660c82
https://doi.org/10.1182/bloodadvances.2022008743
https://doi.org/10.1182/bloodadvances.2022008743
Publikováno v:
Journal of Thrombosis and Haemostasis. 19:2102-2111
New modified coagulation factor VIII (FVIII) and factor IX (FIX) products have been designed to improve the treatment of individuals with hemophilia A and B by increasing the interval between dosing. Although these FVIII and FIX molecules have been s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6204542c6fb598ea4b3bddf828db13c
https://doi.org/10.1111/jth.15425
https://doi.org/10.1111/jth.15425